End Drug Shortages Act
Latest Action
Referred to the House Committee on Energy and Commerce.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The End Drug Shortages Act (H.R. 10239) was a legislative proposal introduced in the 118th Congress aimed at addressing the issue of drug shortages in the United States. The bill was referred to the House Committee on Energy and Commerce but ultimately failed to advance and expired. There is no official summary or full text available for this bill, limiting detailed analysis. The bill falls under the health policy area and presumably sought to implement measures to prevent or mitigate shortages of pharmaceutical drugs, which can impact patient care and public health.
H.R. 10239, the End Drug Shortages Act, was introduced to tackle drug shortages but did not progress beyond committee referral and expired without enactment.
- The bill was introduced in the House during the 118th Congress and referred to the House Committee on Energy and Commerce.
- No official summary or full text is available, so specific provisions and mechanisms are unknown.
- The bill is categorized under the health policy area and addresses drug shortages.
['Patients who require consistent access to medications', 'Healthcare providers relying on stable drug supplies', 'Pharmaceutical industry stakeholders involved in drug manufacturing and distribution', 'Public health agencies concerned with drug availability']
['Lack of available bill text and summary limits understanding of implementation details and enforcement mechanisms', 'Potential costs and funding sources for addressing drug shortages are unknown', 'Oversight and authority provisions cannot be assessed due to missing information', 'Without specific provisions, it is unclear how the bill would balance supply chain regulation with industry flexibility']
The bill was introduced in the House and referred to the Committee on Energy and Commerce but did not advance further, resulting in its expiration. Drug shortages have been a recurring issue in U.S. healthcare policy, often prompting legislative proposals aimed at improving supply chain transparency and responsiveness. The lack of progression suggests either competing legislative priorities or unresolved policy questions at the time.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have influenced pharmaceutical supply chain practices and regulatory oversight, potentially affecting drug availability and pricing.', 'Improved drug shortage management might reduce healthcare disruptions and associated costs.', 'Conversely, regulatory changes could have introduced compliance costs or operational challenges for manufacturers.']
The absence of an official summary and full bill text significantly limits transparency and public understanding of the End Drug Shortages Act. This lack of information restricts the ability to evaluate the bill's scope, mechanisms, and potential impacts fully. For effective government transparency, access to complete legislative texts and summaries is essential to enable informed public and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.